Helix BioMedix EBITDA per Share
The EBITDA per Share of Helix BioMedix (HXBM) as of Oct 18, 2026 is -13.86 USD.
Get this data via API
Financial Data API
EBITDA per Share
-13.86USD
Last updated:
EBITDA per Share of Helix BioMedix is 2011 -13.86 USD. EBITDA per Share of Helix BioMedix was 2010 - USD. It decreases by % lower compared to the previous year.
The Helix BioMedix EBITDA per Share history
| YEAR | EBITDA per Share | YoY |
|---|---|---|
| -13.86USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Helix BioMedix Stock analysis
What does Helix BioMedix do? Helix BioMedix Inc, based in Bothell, Washington, is a biotechnology company operating in the Health Care sector. It focuses on developing topical treatments for rare dermatological diseases, particularly Xeroderma Pigmentosum, using its lead candidate HB4208, a DNA damage response enzyme. The company employs 8 full-time staff and went public on 25 July 2000. Its research leverages bioactive peptides derived from the body's innate immunity to create innovative skin treatments. Helix BioMedix is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Helix BioMedix stock
EBITDA per Share of Helix BioMedix is -13.86 USD in 2011.
On Eulerpool you can find the complete historical development of EBITDA per Share Helix BioMedix since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Helix BioMedix
All Key Metrics — Helix BioMedix
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth